Abstract: A method of forming a functionalized device substrate is provided that includes the steps of: forming a graphene layer on a growth substrate; applying a polyimide layer to a glass, glass-ceramic or ceramic substrate, wherein a coupling agent couples the polyimide layer to the said substrate; coupling the polyimide layer to the graphene layer on the growth substrate; and peeling the growth substrate from the graphene layer.

Abstract: A delamination resistant glass pharmaceutical container may include a glass body comprising a borosilicate glass having a Type 1 chemical durability according to USP <660>. At least an inner surface of the glass body may have a delamination factor less than or equal to 10. A thermally stable coating may be positioned around at least a portion of the outer surface of the glass body. The thermally stable coating may be an outermost coating on the outer surface of the glass body and the outer surface of the glass body with the thermally stable coating has a coefficient of friction less than or equal to 0.7. The thermally stable coating comprising at least one of a metal nitride coating, a metal oxide coating, a metal sulfide coating, SiO2, diamond-like carbon, graphene, and a carbide coating.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include an aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to ISO 720-1985 testing standard. The glass containers may also have a compressive stress layer with a depth of layer of greater than 25 ?m. A surface compressive stress of the glass containers may be greater than or equal to 350 MPa. The delamination resistant glass pharmaceutical containers may be ion exchange strengthened and the ion exchange strengthening may include treating the delamination resistant glass pharmaceutical container in a molten salt bath for a time less than or equal to 5 hours at a temperature less than or equal to 450° C.

Abstract: According to embodiments, a method of making a coated pharmaceutical container, may include: forming a glass tube; forming the glass tube into a pharmaceutical container comprising an interior surface and an exterior surface; and applying a coating to the exterior surface. The coating may have a coefficient of friction less than or equal to 0.7 relative to a second pharmaceutical container when tested in a vial-on-vial testing jig under a normal load of 30 N. The coated pharmaceutical container may be thermally stable after depyrogenation at a temperature of at least 260° C. for 30 minutes in air.

Abstract: Embodiments of the present disclosure are directed to coated glass articles which reduce glass particle formation caused by glass to glass contact in pharmaceutical glass filling lines.

Abstract: A system and process for forming a curved glass laminate article is provided. The process and system utilizes a separation material, such as solid lubricating material and/or a spray applied separation material that Applicant has determined reduces bending dot formation during co-sagging shaping of glass sheets. The bending dot reduction provided by the separation materials discussed herein is particularly seen when the pair of glass sheets have significantly different thicknesses and/or viscosities from each other.

Abstract: Cross-linked shear-thinning fluids of pectic acid demonstrating increased viscosity with decreasing shear, as well as methods of producing and using the same. A shear-thinning fluid includes an aqueous solution of pectic acid cross-linked by a divalent cation is disclosed. The pectic acid may be present in an amount ranging from about 0.5 to about 3.0% (w/v), the divalent cation may be present at a concentration of from about 0.5 mM to about 7.0 mM, and the viscosity of the shear-thinning fluid increases with decreasing shear. These cross-linked shear-thinning fluids of pectic acid can be utilized for controlled release formulations, cell encapsulation, and 3D printing, and provide for an improved balance between structure fidelity/mechanical stability and cell viability.

Abstract: A coated glass package comprising a glass body having a Type 1 chemical durability according to USP 660, at least a class A2 base resistance or better according to ISO 695, and at least a type HGB2 hydrolytic resistance or better according to ISO 719. A lubricous coating having a thickness of ?100 microns may be positioned on at least a portion of the exterior surface of the glass body. The portion of the coated glass package with the lubricous coating comprises a coefficient of friction that is at least 20% less than an uncoated glass package and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation cycle. A horizontal compression strength of the coated glass package is at least 10% greater than an uncoated glass package and the horizontal compression strength is not reduced by more than 20% after undergoing the depyrogenation cycle.

Abstract: Surface modification layers and associated heat treatments, that may be provided on a sheet, a carrier, or both, to control both room-temperature van der Waals (and/or hydrogen) bonding and high temperature covalent bonding between the thin sheet and carrier. The room-temperature bonding is controlled so as to be sufficient to hold the thin sheet and carrier together during vacuum processing, wet processing, and/or ultrasonic cleaning processing, for example. And at the same time, the high temperature covalent bonding is controlled so as to prevent a permanent bond between the thin sheet and carrier during high temperature processing, as well as maintain a sufficient bond to prevent delamination during high temperature processing.

Abstract: A coated glass container having a Type 1 chemical durability according to USP 660 (2011), a class A2 base resistance or better according to ISO 695, and a type HGB2 hydrolytic resistance or better according to ISO 719. The glass body having an interior surface and an exterior surface. A lubricous coating having a thickness of <100 microns positioned on the exterior surface. The portion of the exterior surface with the coating having a coefficient of friction that is at least 20% less than an uncoated glass container formed from the same glass composition and does not increase by more than 30% after undergoing depyrogenation at about 260° C. for 30 minutes. A horizontal compression strength of the coated glass container is at least 10% greater than an uncoated glass container formed from the same glass composition and is not reduced by more than 20% after heat treatment at about 260° C. for 30 minutes.

Abstract: A laser weldable device housing substrate, device housing and related method are provided. The substrate includes a first surface, a second surface opposite the first surface, and a thin inorganic particle layer supported by the first surface. The inorganic particle layer includes a plurality of particles arranged in a layer on the first surface. The particles have an average diameter of less than or equal to 1.0 ?m, and the inorganic particle layer has an average thickness of less than or equal to 5 ?m.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include a glass body having a Class HGA1 hydrolytic resistance when tested according to the ISO 720:1985 testing standard. The glass body may have an interior surface and an exterior surface. The interior surface of the glass body does not comprise a boron-rich layer when the glass body is in an as-formed condition. A heat-tolerant coating may be bonded to at least a portion of the exterior surface of the glass body. The heat-tolerant coating may have a coefficient of friction of less than about 0.7 and is thermally stable at a temperature of at least 250° C. for 30 minutes.

Abstract: In embodiments, a delamination resistant glass pharmaceutical package includes a glass body formed from a Type 1 Class glass composition according to ASTM Standard E438-92, the glass body having a wall portion with an inner surface and an outer surface. The glass body may have at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. An interior region of the glass body may extend from about 10 nm below the inner surface and have a persistent layer homogeneity. The glass body may also have a surface region extending over the inner surface and having a persistent surface homogeneity such that the glass body is resistant to delamination.

Abstract: The glass containers described herein have at least two performance attributes selected from resistance to delamination, improved strength, and increased damage resistance. In one embodiment, a glass container may include a body having an inner surface, an outer surface and a wall thickness extending between the outer surface and the inner surface. At least the inner surface of the body may have a delamination factor less than or equal to 10. A tenacious inorganic coating may be positioned around at least a portion of the outer surface of the body. The outer surface of the body with the tenacious inorganic coating may have a coefficient of friction less than or equal to 0.7.

Abstract: Delamination resistant glass containers with heat-tolerant coatings are disclosed. In one embodiment, a glass container may include a glass body having an interior surface, an exterior surface and a wall thickness extending from the exterior surface to the interior surface. At least the interior surface of the glass body is delamination resistant. The glass container may further include a heat-tolerant coating positioned on at least a portion of the exterior surface of the glass body. The heat-tolerant coating may be thermally stable at temperatures greater than or equal to 260° C. for 30 minutes.

Abstract: Delamination resistant glass containers with heat-tolerant coatings are disclosed. In one embodiment, a glass container may include a glass body having an interior surface, an exterior surface and a wall thickness extending from the exterior surface to the interior surface. At least the interior surface of the glass body is delamination resistant. The glass container may further include a heat-tolerant coating positioned on at least a portion of the exterior surface of the glass body. The heat-tolerant coating may be thermally stable at temperatures greater than or equal to 260° C. for 30 minutes.

Abstract: Glass pharmaceutical packages comprising glass containers are disclosed. In embodiments, a coated glass pharmaceutical package includes a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A lubricous coating may be positioned on at least a portion of the exterior surface of the glass container. The portion of the coated glass pharmaceutical package with the lubricous coating has a coefficient of friction that is at least 20% less than an uncoated glass pharmaceutical package. A horizontal compression strength of the portion of the coated glass pharmaceutical package with the lubricous coating may be at least 10% greater than an uncoated glass pharmaceutical package.

Abstract: A delamination resistant glass pharmaceutical container may include a glass body comprising a borosilicate glass having a Type 1 chemical durability according to USP <660>. At least an inner surface of the glass body may have a delamination factor less than or equal to 10. A thermally stable coating may be positioned around at least a portion of the outer surface of the glass body. The thermally stable coating may be an outermost coating on the outer surface of the glass body and the outer surface of the glass body with the thermally stable coating has a coefficient of friction less than or equal to 0.7. The thermally stable coating comprising at least one of a metal nitride coating, a metal oxide coating, a metal sulfide coating, SiO2, diamond-like carbon, graphene, and a carbide coating.

Abstract: Coated glass pharmaceutical packages are disclosed. According to embodiments, a coated glass pharmaceutical package may include a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating may be bonded to the exterior surface of the glass container. The low-friction coating may include a polymer. The exterior surface of the glass container with the low-friction coating may have a coefficient of friction of less than or equal to 0.7. The coated glass pharmaceutical package may be thermally stable after depyrogenation in air at a temperature of at least about 260° C. for 30 minutes.

Abstract: A glass element having a thickness from 25 ?m to 125 ?m, a first primary surface, a second primary surface, and a compressive stress region extending from the first primary surface to a first depth, the region defined by a compressive stress ?I of at least about 100 MPa at the first primary surface. Further, the glass element has a stress profile such that it does not fail when it is subject to 200,000 cycles of bending to a target bend radius of from 1 mm to 20 mm, by the parallel plate method. Still further, the glass element has a puncture resistance of greater than about 1.5 kgf when the first primary surface of the glass element is loaded with a tungsten carbide ball having a diameter of 1.5 mm.